Announcements Trials
Browse Landscape

Status

Available 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 5Observational 1Expanded_access 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 13Neoplasms 11Recurrence 9Multiple Myeloma 9Pancreatic Neoplasms 8Prostatic Neoplasms 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Neuroblastoma 6Melanoma 6Sarcoma 5Ovarian Neoplasms 5Leukemia, Myeloid, Acute 5Hematologic Neoplasms 4Glioblastoma 4Colorectal Neoplasms 4Breast Neoplasms 4Stomach Neoplasms 3Osteosarcoma 3Non-Muscle Invasive Bladder Neoplasms 3Neuroectodermal Tumors, Primitive 3Myelodysplastic Syndromes 3Lymphoma, Large B-Cell, Diffuse 3Lung Neoplasms 3Head and Neck Neoplasms 3Carcinoma, Squamous Cell 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Primary Myelofibrosis 2Polycythemia Vera 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × Pancreatic Ductal Adenocarcinoma (PDAC) × 1 year × Clear all
NCT07612930 2026-05-29

Expanded Access to PCNAT-01 for Patients With Resected Pancreatic Ductal Adenocarcinoma Following Surgical Resection and Adjuvant Therapy

Anda Biopharmaceutical Development (Shenzhen) Co., Ltd.

Available
Gastrointestinal

Pancreatic Ductal Adenocarcinoma (PDAC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡